KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Net Margin: 2011-2025

Historic Net Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -23.49%.

  • Supernus Pharmaceuticals' Net Margin fell 4540.00% to -23.49% in Q3 2025 from the same period last year, while for Sep 2025 it was -2.80%, marking a year-over-year decrease of 1195.00%. This contributed to the annual value of 11.16% for FY2024, which is 1094.00% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Net Margin of -23.49% as of Q3 2025, which was down 272.71% from 13.60% recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Net Margin registered a high of 21.91% during Q3 2024, and its lowest value of -23.49% during Q3 2025.
  • For the 3-year period, Supernus Pharmaceuticals' Net Margin averaged around 2.33%, with its median value being 0.72% (2023).
  • In the last 5 years, Supernus Pharmaceuticals' Net Margin spiked by 3,232bps in 2024 and then plummeted by 4,540bps in 2025.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Net Margin stood at 1.54% in 2021, then spiked by 1,369bps to 15.23% in 2022, then tumbled by 1,451bps to 0.72% in 2023, then soared by 811bps to 8.83% in 2024, then slumped by 4,540bps to -23.49% in 2025.
  • Its Net Margin stands at -23.49% for Q3 2025, versus 13.60% for Q2 2025 and -7.90% for Q1 2025.